IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/588,323

Confirmation No. 2783

Applicant: MAGILAVY

Filing/371(c) Date: February 16, 2007

TC/AU: 1644

Examiner: Unassigned

Docket No.: 253780

Customer No.: 23460

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner initial the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

\boxtimes	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.		
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:		
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).	
	- or	_	
		the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).	
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).		
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.		
Copies of the References			
	Copie:	s of all of the references listed on the enclosed Form 1449 are enclosed ith.	
	Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.		
	concis Englis action	sch reference not in the English language, attached is an English translation, a see explanation of relevance, an English-language equivalent/patent, an sh-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the e of relevance found by the foreign office pursuant to 37 CFR 1.98(a)(3).	

Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Fees

\boxtimes	No fee is owed by the applicant(s).
\square	Charge Deposit Account No. 12-1216 in the amount of \$180.00 (37 CFR 1.17(p))
	(A duplicate copy of this communication is enclosed for that purpose, unless
	submitted via EFS-Web.)

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose, unless submitted via EFS-Web.)

Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

Christine M. Cochran, Reg. No. 52,757 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6731 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: January 23, 2008